Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research report report published on Sunday morning. The brokerage issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Price Performance

Brooklyn ImmunoTherapeutics stock opened at $0.21 on Friday. The stock has a market capitalization of $12.07 million, a price-to-earnings ratio of -0.85 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a 1-year low of $0.17 and a 1-year high of $10.10. The business has a fifty day moving average price of $2.02 and a 200-day moving average price of $1.99.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.